Financials

	2022	2023
Net sales	54.13M 47.44M 43.86M 40.33M 76.21M 5.22B 77.41M 523M 205M 2.55B 203M 199M 8.79B	80.75M 70.78M 65.43M 60.17M 114M 7.79B 115M 781M 306M 3.81B 303M 297M 13.12B
Net income	-18.11M -15.87M -14.67M -13.49M -25.49M -1.75B -25.9M -175M -68.66M -854M -67.99M -66.51M -2.94B	-20.13M -17.65M -16.31M -15M -28.34M -1.94B -28.79M -195M -76.34M -950M -75.59M -73.94M -3.27B
Net Debt	42.09M 36.89M 34.1M 31.36M 59.26M 4.06B 60.2M 407M 160M 1.99B 158M 155M 6.84B	55.34M 48.5M 44.84M 41.23M 77.91M 5.34B 79.15M 535M 210M 2.61B 208M 203M 8.99B

* Estimated data More financial data

Company Profile

Alimera Sciences, Inc. is a global pharmaceutical company. The Company is focused on helping patients, physicians and partners concerned with retinal health and maintaining better vision longer.

Employees

157

Sector

Pharmaceuticals

More about the company

Income Statement and Estimates

More financial data

Market Closed - Nasdaq Other stock markets 00:00:00 14/09/2024 +04			5-day change	1st Jan Change
5.540 ^USD	-0.18%		-.--%	-

16/09/24	ANI Pharmaceuticals Completes Purchase of Alimera Sciences, Sees 'Substantially Higher' Earnings After Deal	MT
16/09/24	Alimera Sciences, Inc.(NasdaqGM:ALIM) dropped from NASDAQ Composite Index	CI

Market Cap	301M 264M 244M 224M 424M 29.05B 431M 2.91B 1.14B 14.21B 1.13B 1.11B 48.95B	P/E 2022	-1.05x	P/E 2023	-5.16x
Enterprise Value	357M 313M 289M 266M 502M 34.39B 510M 3.45B 1.35B 16.82B 1.34B 1.31B 57.94B	EV / Sales 2022	1.13x	EV / Sales 2023	3.49x
Free-Float	94.65%	Yield 2022 *	-	Yield 2023	-

16/09/24	ANI Pharmaceuticals Completes Purchase of Alimera Sciences, Sees 'Substantially Higher' Earnings After Deal	MT
16/09/24	Alimera Sciences, Inc.(NasdaqGM:ALIM) dropped from NASDAQ Composite Index	CI
16/09/24	ANI Pharmaceuticals, Inc. completed the acquisition of Alimera Sciences, Inc. from Caligan Partners Master Fund LP and Caligan Partners Master Fund LP, managed by Caligan Partners, LP and others.	CI
11/09/24	Exchange-Traded Funds, Equity Futures Lower Pre-Bell Wednesday as Looming CPI Data Likely to Provide Rate-Cut Clues	MT
11/09/24	ANI Pharmaceuticals, Alimera Sciences to Close Merger Next Week	MT
10/09/24	Alimera Sciences Sues ANI Pharmaceuticals for Delays in Merger Close	MT
10/09/24	Alimera Sciences, Inc.(NasdaqGM:ALIM) dropped from S&P TMI Index	CI
06/08/24	Alimera Sciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024	CI
17/07/24	Processa Pharmaceuticals Appoints Russell Skibsted as CFO	MT
01/07/24	Alimera Sciences, Inc.(NasdaqGM:ALIM) added to Russell Small Cap Comp Value Index	CI
01/07/24	Alimera Sciences, Inc.(NasdaqGM:ALIM) added to Russell Small Cap Completeness Index	CI
01/07/24	Alimera Sciences, Inc.(NasdaqGM:ALIM) added to Russell 2000 Index	CI
01/07/24	Alimera Sciences, Inc.(NasdaqGM:ALIM) added to Russell 3000E Index	CI

25/06/24	Maxim Downgrades Alimera Sciences to Hold From Buy	MT
25/06/24	Alliance Global Partners Downgrades Alimera Sciences to Neutral From Buy, Adjusts Price Target to $5.50 From $8	MT
25/06/24	Craig-Hallum Downgrades Alimera Sciences to Hold From Buy, Price Target is $5.50	MT
25/06/24	HC Wainwright Downgrades Alimera Sciences to Neutral From Buy, Price Target is $6	MT
25/03/24	Maxim Initiates Alimera Sciences at Buy Rating With $10 Price Target	MT

Alimera Sciences, Inc. Stock

Stocks

ALIM

US0162592028

Pharmaceuticals

Valuation: Alimera Sciences, Inc.

Latest news : Alimera Sciences, Inc.

Analysts' recommendations: Alimera Sciences, Inc.

Press Releases: Alimera Sciences, Inc.

News in other languages: Alimera Sciences, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Alimera Sciences, Inc.

Latest insider transactions

Biopharmaceuticals

Financials

Company Profile

Income Statement and Estimates

16/09/24	ANI Pharmaceuticals, Inc. Completes Acquisition of Alimera Sciences	AQ
11/09/24	ANI Pharmaceuticals and Alimera Sciences Announce Closing Date of Merger	BU
11/09/24	ANI Pharmaceuticals and Alimera Sciences Announce Closing Date of Merger	AQ
10/09/24	ANI Pharmaceuticals Provides Update on Closing of Acquisition of Alimera Sciences	AQ
10/09/24	Alimera Sciences Takes Legal Action Against ANI Pharmaceuticals to Enforce Merger Agreement	BU

Manager	Title	Age	Since
Elliot Maltz DFI	Director of Finance/CFO	41	02/01/2024
Jason Werner COO	Chief Operating Officer	48	02/10/2023
Laura Cegala HRO	Human Resources Officer	-	-

Date	Insider	Type	Main position	Quantity	% Market Cap.
16/09/24	Velan Capital Investment Management LP	Issuer sale	Company	14,408,533	26.4940%
16/09/24	Elliot Maltz	Issuer sale	Chief Financial Officer	225,000	0.4137%
16/09/24	Michael Kaseta	Issuer sale	Director	51,825	0.0953%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ALIMERA SCIENCES, INC.	-0.18%	-.--%	-.--%	+45.79%	287M
REGENERON PHARMACEUTICALS, INC.	-0.67%	+1.15%	+23.89%	-6.52%	68.85B
UCB	-0.54%	+0.38%	+36.12%	+192.81%	52.13B
SAMSUNG BIOLOGICS CO.,LTD.	-3.65%	+34.50%	+34.50%	+34.50%	43.46B
CSL LIMITED	-0.58%	-0.23%	-52.36%	-53.82%	41.24B
BIOGEN INC.	-2.93%	+0.40%	+59.97%	-27.79%	30.41B
MODERNA, INC.	-3.77%	-12.86%	+90.31%	-52.47%	24.53B
INCYTE CORPORATION	-1.36%	-0.91%	+70.42%	+83.86%	23.42B
INNOVENT BIOLOGICS, INC.	+3.99%	+3.12%	+3.87%	+200.81%	19.75B
SWEDISH ORPHAN BIOVITRUM AB	+0.26%	-1.74%	+70.47%	+125.19%	16.57B
Average	-0.57%	-0.92%	+33.72%	+54.24%	32.06B
Weighted average by Cap.	-0.92%	-0.46%	+30.56%	+46.06%

3 years	2.61	5.65
5 years	1.3	9.79
10 years	0	36